NeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical: NeuroVive Pharmaceutical AB Interim Report January - March 2019
First subjects enrolled in the KL1333 study
Important events January-March 2019
NeuroVive enrolls first subject in its KL1333 phase Ia/b clinical
NeuroVive is supplied with approximately MSEK 99.0 in share issue
NeuroVive receives SEK 28.2 Million in a directed new share issue.
NeuroVive enters commercial partnership with Oroboros Instruments
on mitochondrial medicine research compounds.
Important events after the reporting period
The Supreme Court had delivered its ruling concerning arbitration
between NeuroVive and CicloMulsion AG. NeuroVive appealed to the
Supreme Court on certain points. The Supreme Court has rejected the
The US Food and Drug Administration, FDA, has approved NeuroVives
IND (Investigational New Drug) application, enabling clinical studies
in the US with the companys drug candidate NeuroSTAT.
Financial information January-March 2019
Net revenues: KSEK 0 (0)
Other operating income: KSEK 0 (174)
Loss before tax: KSEK -13,822 (-13,053)
Loss per share:* SEK -0,12 (-0,25)
Diluted loss per share:** SEK -0,12 (-0,25)
* Profit/loss for the period divided by average number of shares
before dilution at the end of the period.
** Profit/loss for the period divided by average number of shares
after dilution at the end of the period.
Please find the complete interim report attached below, or through our
The information was submitted for publication, through the agency of
the contact person set out below, at 08:30 a.m. CEST on 21 May 2019.
For more information, please contact:
Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, email@example.com
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
For news subscription, please visit
Follow us on LinkedIn
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine,
with one project in clinical phase I (KL1333) for genetic
mitochondrial diseases and one project in preparation for a clinical
phase II efficacy study for the prevention of moderate to severe
traumatic brain injury (NeuroSTAT). The R&D portfolio also consists
of projects for genetic mitochondrial disorders, NASH and cancer. The
company advances drugs for rare diseases through clinical development
into the market, with or without partners. For projects for common
indications the goal is out-licensing in the preclinical phase. A
subset of compounds under NeuroVives NVP015 program has been
licenced to Fortify Therapeutics, a BridgeBio company, for local
treatment development of Lebers Hereditary Optic Neuropathy (LHON).
NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The
share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).